摘要
目的研究美托洛尔联合曲美他嗪治疗冠心病心力衰竭的临床疗效。方法50例冠心病心力衰竭患者,随机分为实验组和对照组,每组25例。实验组患者采用美托洛尔联合曲美他嗪治疗,对照组患者采用美托洛尔治疗。比较两组患者左心室射血分数、用药不良反应发生情况、治疗效果。结果治疗后,实验组患者左心室射血分数为(51.2±5.8)%,显著高于对照组的(46.1±4.9)%,差异具有统计学意义(P<0.05)。两组患者用药不良反应发生率比较差异无统计学意义(P>0.05)。实验组患者总有效率为88.0%,高于对照组的60.0%,差异具有统计学意义(P<0.05)。结论冠心病心力衰竭采用美托洛尔联合曲美他嗪治疗效果显著,能够提高患者心功能,且不良反应较少,值得临床推广应用。
Objective To study the clinical efficacy of metoprolol combined with trimetazidine in the treatment of coronary heart disease and heart failure.Methods A total of 50 cases of coronary heart disease and heart failure were randomly divided into experimental group and control group,with 25 cases in each group.The experimental group was treated by metoprolol combined with trimetazidine,and the control group was treated by metoprolol.The left ventricular ejection fraction,occurrence of adverse drug reactions and therapeutic effect between the two groups was compared.Results After treatment,the left ventricular ejection fraction was(51.2±5.8)%in the experimental group,which was significantly higher than(46.1±4.9)%in the control group,and the difference was statistically significant(P<0.05).There was no statistically significant difference in incidence of adverse drug reactions between the two groups(P>0.05).The total effective rate was 88.0%in the experimental group,which was higher than 60.0%in the control group,and the difference was statistically significant(P<0.05).Conclusion Metoprolol combined with trimetazidine shows remarkable therapeutic effect in the treatment of coronary heart disease and heart failure,and it can improve the cardiac function of patients with less adverse reactions.It is worthy of clinical promotion and application.
作者
王小霞
WANG Xiao-xia(Department of Internal Medicine,Taixing Hospital of Traditional Chinese Medicine,Taixing 225400,China)
出处
《中国实用医药》
2019年第33期82-83,共2页
China Practical Medicine
